Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
1.000
+0.090 (9.89%)
At close: Nov 19, 2026, 4:00 PM EST
1.000
0.00 (0.00%)
After-hours: Nov 19, 2026, 7:30 PM EST
Aardvark Therapeutics Employees
Aardvark Therapeutics had 28 employees as of June 30, 2026. The number of employees decreased by 3 or 9.68% compared to the same quarter last year. That makes Aardvark Therapeutics the 37,318th largest employer in the world and 5,187th in the United States.
Employees
28
Change (1Y)
-3
Growth (1Y)
-9.68%
Revenue / Employee
n/a
Profits / Employee
-$2,598,536
Market Cap
21.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 28 | -3 | -9.68% | 28 | 0 |
| Mar 31, 2026 | 40 | 14 | 53.85% | 40 | 0 |
| Dec 31, 2025 | 40 | 18 | 81.82% | 40 | 0 |
| Sep 30, 2025 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2025 | 31 | 17 | 121.43% | 31 | 0 |
| Mar 31, 2025 | 26 | 12 | 85.71% | 26 | 0 |
| Dec 31, 2024 | 22 | - | - | 22 | 0 |
| Sep 30, 2024 | 18 | - | - | 17 | 1 |
| Jun 30, 2024 | 14 | - | - | 12 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 113 |
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| Evaxion | 46 |
| BriaCell Therapeutics | 31 |
| INmune Bio | 21 |
| Edesa Biotech | 17 |
| ProMIS Neurosciences | 11 |
AARD News
- 6 days ago - Aardvark Therapeutics reports Q3 EPS (88c), consensus (75c) - TheFly
- 6 days ago - Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 days ago - Aardvark Therapeutics Quarterly report: Q3 2026 - Filings
- 6 days ago - Aardvark Therapeutics Earnings release: Q3 2026 - Filings
- 15 days ago - Aardvark Therapeutics downgraded to Market Perform from Strong Buy at Raymond James - TheFly
- 23 days ago - Aardvark Therapeutics price target lowered to $10 from $19 at Jones - TheFly
- 24 days ago - Aardvark Therapeutics downgraded to Perform from Outperform at Oppenheimer - TheFly
- 24 days ago - Aardvark Therapeutics price target lowered to $2 from $4 at H.C. Wainwright - TheFly